MoonLake Immunotherapeutics Faces Class Action Lawsuit
The Law Offices of Frank R. Cruz has recently announced that a class action lawsuit has been initiated on behalf of shareholders who invested in MoonLake Immunotherapeutics (NASDAQ: MLTX). This action pertains to individuals who acquired common stock between March 10, 2024, and September 29, 2025. Shareholders have a deadline to file a lead plaintiff motion by December 15, 2025.
Understanding the Legal Background
This lawsuit is significant for investors, especially those who may have suffered losses due to recent financial disclosures. The law firm encourages any affected shareholder to inquire about their rights and participate in this collective legal effort. If you experienced financial setbacks related to your investment in MoonLake Immunotherapeutics, reaching out to legal representatives may provide avenues for recovery.
What Triggered the Lawsuit?
The catalyst for this class action was an announcement by MoonLake Immunotherapeutics regarding disappointing results from its Phase 3 trials for its primary drug candidate, sonelokimab (SLK). On September 28, 2025, the company disclosed that SLK failed to achieve the efficacy benchmarks set by its competitor, Union Chimique Belge's bimekizumab-bkz (BIMZELX). This revelation was particularly alarming as the company had touted SLK's unique nanobody structure as a superior option. However, it became apparent that SLK targeted the same inflammatory cytokines and had no proven clinical advantages over existing treatments.
Impact on Shareholder Value
Following the announcement of the trial results, the market reacted sharply. MoonLake's stock plummeted by an astounding $55.74, which is a staggering 89.9% decline, leaving the stock price at just $6.24 per share by September 29, 2025. Such a dramatic drop undoubtedly harmed investors and raised questions about the company's prior disclosures.
Lawsuit Details and Allegations
The class action complaint alleges that throughout the specified Class Period, the defendants engaged in misleading practices by making false statements and failing to reveal crucial adverse facts regarding the company's business performance and future prospects. Key allegations include a lack of disclosure about the similarities between SLK and BIMZELX, concerns about SLK's clinical efficacy, and a rise in misleading positive statements regarding the company’s operations.
Take Action: Your Rights as an Investor
If you are a shareholder of MoonLake Immunotherapeutics and wish to comprehend your rights or learn more about this ongoing class action, consider reaching out to legal professionals. The Law Offices of Frank R. Cruz offer a pathway for interested parties to understand the implications of the lawsuit and the steps they can take.
Contact Information
For further inquiries or to explore your participation in the class action, you can reach out via email or telephone. Contact the Law Offices of Frank R. Cruz by emailing info@frankcruzlaw.com or calling (310) 914-5007. You can also visit the firm’s website for more details and resources.
Frequently Asked Questions
What is the class action lawsuit regarding MoonLake Immunotherapeutics?
The class action lawsuit concerns disclosures related to MoonLake's Phase 3 trial results for sonelokimab and potential damages incurred by shareholders.
Who can participate in the lawsuit?
Shareholders who purchased MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible to participate in the class action.
What happened to MoonLake's stock?
Following disappointing trial results announced on September 28, 2025, MoonLake's stock fell dramatically by nearly 90% the next day.
How can I claim participation in the lawsuit?
Interested shareholders should contact the Law Offices of Frank R. Cruz to learn about their rights and how to file claims.
What is the deadline for claims?
The deadline for filing a lead plaintiff motion is December 15, 2025.
